These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 30355544)
1. Pegylated interferon-α2b for local control of Langerhans cell sarcoma. Ishitsuka Y; Iwamoto K; Oya K; Nakamura Y; Watanabe R; Okiyama N; Fujisawa Y; Fujimoto M Eur J Dermatol; 2018 Dec; 28(6):835-836. PubMed ID: 30355544 [No Abstract] [Full Text] [Related]
2. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy. Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409 [No Abstract] [Full Text] [Related]
3. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma. Agarwala SS Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109 [TBL] [Abstract][Full Text] [Related]
4. The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a's role in treating mycosis fungoides/Sézary syndrome. Stadler R Br J Dermatol; 2024 Aug; 191(3):321-322. PubMed ID: 38703059 [No Abstract] [Full Text] [Related]
5. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature. Lawson BO; Khong HT Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304 [TBL] [Abstract][Full Text] [Related]
6. A case of an adult Langerhans cell sarcoma. Ma X; Li W; Du J; Cai L; Zhang J Int J Dermatol; 2016 Jan; 55(1):92-6. PubMed ID: 25312302 [No Abstract] [Full Text] [Related]
7. Effective control of rush progression of CD8+ mycosis fungoides with pegylated interferon. Fujimura T; Okuyama R; Hashimoto A; Watanabe H; Nakagawa S; Tagami H; Aiba S Acta Derm Venereol; 2006; 86(2):161-2. PubMed ID: 16648924 [No Abstract] [Full Text] [Related]
8. Langerhans cell sarcoma emanating from the upper arm skin: successful treatment by MAID regimen. Uchida K; Kobayashi S; Inukai T; Noriki S; Imamura Y; Nakajima H; Yayama T; Orwotho N; Baba H J Orthop Sci; 2008 Jan; 13(1):89-93. PubMed ID: 18274862 [No Abstract] [Full Text] [Related]
9. Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase? Quintás-Cardama A; Verstovsek S Leuk Lymphoma; 2007 Mar; 48(3):445-6. PubMed ID: 17454579 [No Abstract] [Full Text] [Related]
10. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216 [TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis. Messori A; Fadda V; Maratea D; Trippoli S; Marinai C Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456 [No Abstract] [Full Text] [Related]
12. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera. Wagner SM; Melchardt T; Greil R Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866 [TBL] [Abstract][Full Text] [Related]
13. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? Tarhini AA; Kirkwood JM J Clin Oncol; 2012 Nov; 30(31):3773-6. PubMed ID: 23008298 [No Abstract] [Full Text] [Related]
14. Clinical benefits of pegylated proteins in oncology. Crawford J Cancer Treat Rev; 2002 Apr; 28 Suppl A():1-2. PubMed ID: 12173406 [No Abstract] [Full Text] [Related]
15. Cutaneous Langerhans cell sarcoma relapsing systemically: Complete remission with the EPIG regimen. Kwong YL Ann Hematol; 2015 Apr; 94(4):697-9. PubMed ID: 25186787 [No Abstract] [Full Text] [Related]
16. The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides. Patsatsi A; Papadavid E; Kyriakou A; Georgiou E; Koletsa T; Avgeros C; Koumourtzis M; Lampadaki K; Tsamaldoupis A; Lazaridou E; Stratigos A; Nikolaou V J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e291-e293. PubMed ID: 34753217 [No Abstract] [Full Text] [Related]